Literature DB >> 1031549

Serum lipids and lipoproteins in chronic liver disease.

J Fehér, L Romics, L Jakab, E Fehér, I Szilvási, G Papp.   

Abstract

Serum cholesterol, triglyceride, total lipids and the lipoprotein pattern were studied in 169 cases chronic liver disease confirmed by biopsy. On the ground of the immunological and morphological results the patients were classified into five groups. In chronic persistent hepatitis no significant abnormality was found. In chronic aggressive hepatitis and in cirrhosis of the liver the serum cholesterol level was significantly reduced. In fatty infiltration of the liver the serum cholesterol, triglyceride and total lipid concentrations were significantly increased, as compared with the normal values and with the figures obtained in the cases of chronic inflammatory liver disease. In the cases of cirrhosis with additional diabetes the lipid values were likewise increased. In chronic aggressive hepatitis and in cirrhosis of the liver the levels of pre-beta and alpha lipoprotein were decreased, in fatty infiltration of the liver those of beta and pre-beta lipoprotein were increased.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1031549

Source DB:  PubMed          Journal:  Acta Med Acad Sci Hung        ISSN: 0001-5989


  3 in total

1.  Low plasma apolipoprotein A-I level is not a reliable marker of fibrosis in children with chronic hepatitis B.

Authors:  Mukadder-Ayse Selimoglu; Rasit-Vural Yagcl; Gül Yüce
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

2.  Hepatitis B virus-mediated changes of apolipoprotein mRNA abundance in cultured hepatoma cells.

Authors:  Pamela A Norton; Qiaoke Gong; Anand S Mehta; Xuanyong Lu; Timothy M Block
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

3.  Metabolic Dysregulation in Hepacivirus Infection of Common Marmosets (Callithrix jacchus).

Authors:  Cordelia Manickam; Lynn Wachtman; Amanda J Martinot; Luis D Giavedoni; R Keith Reeves
Journal:  PLoS One       Date:  2017-01-13       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.